CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin
- Authors
- Jang, Yeonwoo; Cho, Young Seok; Kim, April; Zhou, Xingwu; Kim, Yujin; Wan, Ziye; Moon, James J.; Park, Hansoo
- Issue Date
- Mar-2024
- Publisher
- AMER CHEMICAL SOC
- Keywords
- macrophage-membrane-derived vesicle; membraneengineering; biomimetic hybrid vesicle; combinationtherapy; cancer immunotherapy; metalloimmunotherapy
- Citation
- ACS APPLIED MATERIALS & INTERFACES, v.16, no.14, pp 17129 - 17144
- Pages
- 16
- Journal Title
- ACS APPLIED MATERIALS & INTERFACES
- Volume
- 16
- Number
- 14
- Start Page
- 17129
- End Page
- 17144
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73328
- DOI
- 10.1021/acsami.3c18569
- ISSN
- 1944-8244
1944-8252
- Abstract
- Immune-cell-derived membranes have garnered significant attention as innovative delivery modalities in cancer immunotherapy for their intrinsic immune-modulating functionalities and superior biocompatibilities. Integrating additional parental cell membranes or synthetic lipid vesicles into cellular vesicles can further potentiate their capacities to perform combinatorial pharmacological activities in activating antitumor immunity, thus providing insights into the potential of hybrid cellular vesicles as versatile delivery vehicles for cancer immunotherapy. Here, we have developed a macrophage-membrane-derived hybrid vesicle that has the dual functions of transporting immunotherapeutic drugs and shaping the polarization of tumor-associated macrophages for cancer immunotherapy. The platform combines M1 macrophage-membrane-derived vesicles with CXCR4-binding-peptide-conjugated liposomes loaded with manganese and doxorubicin. The hybrid nanovesicles exhibited remarkable macrophage-targeting capacity through the CXCR4-binding peptide, resulting in enhanced macrophage polarization to the antitumoral M1 phenotype characterized by proinflammatory cytokine release. The manganese/doxorubicin-loaded hybrid vesicles in the CXCR4-expressing tumor cells evoked potent cancer cytotoxicity, immunogenic cell death of tumor cells, and STING activation. Moreover, cotreatment with manganese and doxorubicin promoted dendritic cell maturation, enabling effective tumor growth inhibition. In murine models of CT26 colon carcinoma and 4T1 breast cancer, intravenous administration of the manganese/doxorubicin-loaded hybrid vesicles elicited robust tumor-suppressing activity at a low dosage without adverse systemic effects. Local administration of hybrid nanovesicles also induced an abscessive effect in a bilateral 4T1 tumor model. This study demonstrates a promising biomimetic manganese/doxorubicin-based hybrid nanovesicle platform for effective cancer immunotherapy tailored to the tumor microenvironment, which may offer an innovative approach to combinatorial immunotherapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of ICT Engineering > School of Integrative Engineering > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73328)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.